Some Science of Pro 140 (PA14) (Leronlimab) ccr5 cydy

New Post Public Reply Private Reply Replies (1) Message Board
trding
10,227
Some Science of Pro 140 (PA14) (Leronlimab) ccr5 cydy cytodyn tnbc nash hiv

Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5
William C. Olson, Gwénaël E. E. Rabut, Kirsten A. Nagashima, Diep N. H. Tran, Deborah J. Anselma, Simon P. Monard, Jeremy P. Segal, Daniah A. D. Thompson, Francis Kajumo, Yong Guo, John P. Moore, Paul J. Maddon, Tatjana Dragic
Journal of Virology May 1999, 73 (5) 4145-4155;
https://jvi.asm.org/content/73/5/4145.short


Potent, Broad-Spectrum Inhibition of Human Immunodeficiency Virus Type 1 by the CCR5 Monoclonal Antibody PRO 140
Alexandra Trkola, Thomas J. Ketas, Kirsten A. Nagashima, Lu Zhao, Tonie Cilliers, Lynn Morris, John P. Moore, Paul J. Maddon, William C. Olson
Journal of Virology Jan 2001, 75 (2) 579-588
https://jvi.asm.org/content/75/2/579.short

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
Alexandra Trkola, Shawn E. Kuhmann, Julie M. Strizki, Elizabeth Maxwell, Tom Ketas, Tom Morgan, Pavel Pugach, Serena Xu, Lisa Wojcik, Jayaram Tagat, Anandan Palani, Sherry Shapiro, John W. Clader, Stuart McCombie, Gregory R. Reyes, Bahige M. Baroudy, and John P. Moore
PNAS January 8, 2002 99 (1) 395-400
https://www.pnas.org/content/99/1/395.short


HIV entry inhibitors: mechanisms of action and resistance pathways
Verónica Briz, Eva Poveda, Vincent Soriano
Journal of Antimicrobial Chemotherapy, Volume 57, Issue 4, April 2006, Pages 619–627,
https://academic.oup.com/jac/article/57/4/619/669426


Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140)
Shearer, William T; DeVille, Jaime G; Samson, Pearl M; Moye, John H; Fletcher, Courtney V
Journal of Allergy and Clinical Immunology; St. Louis Vol. 118, Iss. 2, (Aug 2006): 518-521
https://search.proquest.com/openview/35e40dec...806d0113/1

An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry
Diana Safariana Xavier Carneca,Fotini Tsamisa, Francis Kajumoab, Tatjana Dragica
Virology
Volume 352, Issue 2, 1 September 2006, Pages 477-484
https://www.sciencedirect.com/science/article...2206003369

Potent Antiviral Synergy between Monoclonal Antibody and Small-Molecule CCR5 Inhibitors of Human Immunodeficiency Virus Type 1
Jose D. Murga, Michael Franti, Daniel C. Pevear, Paul J. Maddon, William C. Olson
Antimicrobial Agents and Chemotherapy Sep 2006, 50 (10) 3289-3296;
https://aac.asm.org/content/50/10/3289.short


HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
Pavel Pugach, Andre Marozsan, Thomas Ketas, Elissa Landes, John Moore, Shawn Kuhmann
Virology Volume 361, Issue 1, 25 April 2007, Pages 212-228
https://www.sciencedirect.com/science/article...2206008245

Antiviral Activity of Single-Dose PRO 140, a CCR5 Monoclonal Antibody, in HIV-Infected Adults
Jeffrey M. Jacobson, Michael S. Saag, Melanie A. Thompson, Margaret A. Fischl, Ralph Liporace, Richard C. Reichman, Robert R. Redfield, Carl J. Fichtenbaum, Barry S. Zingman, Mahesh C. Patel, Jose D. Murga, Suzanne M. Pemrick, Paul D'Ambrosio, Marti Michael, Hans Kroger, Hieu Ly, Yakov Rotshteyn, Robert Buice, Stephen A. Morris, Joseph J. Stavola, Paul J. Maddon, Alton B. Kremer, William C. Olson
The Journal of Infectious Diseases, Volume 198, Issue 9, 1 November 2008, Pages 1345–1352
https://academic.oup.com/jid/article/198/9/1345/834086

Single-Dose PRO 140 Has Lasting Effects
Tim Horn, 21 Sept 2007. POZ.com
https://www.poz.com/article/Single-Dose-PRO-1...13079-7759


ICAAC: Phase 1 study provides `proof of concept` for PRO 140, a monoclonal CCR5 antibody
Derek Thaczuk, 21 September 2007
https://www.aidsmap.com/news/sep-2007/icaac-p...5-antibody


New approaches in the treatment of HIV/AIDS – focus on maraviroc and other CCR5 antagonists
Hans P Schlecht, Sarah Schellhorn, Bruce J Dezube, and Jeffrey M Jacobson
Ther Clin Risk Manag. 2008 Apr; 4(2): 473–485.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2504054/


CCR5 Monoclonal Antibodies for HIV-1 Therapy
William C. Olson and Jeffrey M. Jacobson
Curr Opin HIV AIDS. 2009 Mar; 4(2): 104–111.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760828/

Phase 2a Study of the CCR5 Monoclonal Antibody PRO 140 Administered Intravenously to HIV-Infected Adults
Jeffrey M. Jacobson, Jacob P. Lalezari, Melanie A. Thompson, Carl J. Fichtenbaum, Michael S. Saag, Barry S. Zingman, Paul D'Ambrosio, Nancy Stambler, Yakov Rotshteyn, Andre J. Marozsan, Paul J. Maddon, Stephen A. Morris, William C. Olson
Antimicrobial Agents and Chemotherapy Sep 2010, 54 (10) 4137-4142
https://aac.asm.org/content/54/10/4137.short


Anti-HIV-1 Activity of Weekly or Biweekly Treatment with Subcutaneous PRO 140, a CCR5 Monoclonal Antibody
Jeffrey M. Jacobson, Melanie A. Thompson, Jacob P. Lalezari, Michael S. Saag, Paul Zingman, Barry S. D'Ambrosio, Nancy Stambler, Yakov Rotshteyn, Andre J. Marozsan, Paul J. Maddon, Stephen A. Morris, William C. Olson
The Journal of Infectious Diseases, Volume 201, Issue 10, 15 May 2010, Pages 1481–1487
https://academic.oup.com/jid/article/201/10/1481/992206

PRO 140 - A Novel CCR5 Co-Receptor Inhibitor
Khatib, Nadia; Das, Satyajit
Recent Patents on Anti-Infective Drug Discovery, Volume 5, Number 1, 2010, pp. 18-22(5)
https://www.ingentaconnect.com/content/ben/pr...1/art00003

The Monoclonal CCR5 Antibody PRO-140: The Promise of Once-Weekly HIV Therapy
Jacobson JM, Thompson MA, Lalezari JP, et al.: Anti–HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.
Journal Infect Dis 2010, 201:1481–1487.
https://link.springer.com/article/10.1007/s11904-010-0068-y


Combinatorial Approaches to the Prevention and Treatmentof HIV-1 Infection
Pirrone V, Thakkar N, Jacobson JM, Wigdahl B, Krebs FC.
Antimicrob Agents Chemother. 2011 May;55(5):1831-42
https://www.ncbi.nlm.nih.gov/pubmed/21343462

Synergistic Inhibition of R5 HIV-1 by Maraviroc and CCR5 Antibody HGS004 in Primary Cells: Implications for Treatment and Prevention
OLGA LATINOVIC,a NHUT LE,a MARVIN REITZ,a RANAJIT PAL,b ANTHONY DEVICO,a JAMES S. FOULKE,a ROBERT R. REDFIELD,a and ALONSO HEREDIAa
AIDS. 2011 Jun 1; 25(9): 1232–1235.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748726/


Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection.
Li L, Tian JH, Yang K, Zhang P, Jia WQ.
Cochrane Database Syst Rev. 2014 Jul 26 7):CD008439.
https://www.ncbi.nlm.nih.gov/pubmed/25063928


PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice.
Bioliogy Blood Marrow Transplant. 2018 Feb;24(2):260-266
Burger DR, Parker Y, Guinta K, Lindner D.
https://www.ncbi.nlm.nih.gov/pubmed/29128556



PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection
Dhody K, Pourhassan N, Kazempour K, Green D, Badri S, Mekonnen H, Burger D, Maddon PJ
HIV Clin Trials. 2018 Jun;19(3):85-93
https://www.ncbi.nlm.nih.gov/pubmed/29676212



The return of PRO 140, a CCR5-directed mAb
Thompson MA
Current Opinion HIV AIDS. 2018 Jul;13(4):346-353
https://www.ncbi.nlm.nih.gov/pubmed/29708899


PRO 140 Single-Agent Maintenance Therapy for HIV-1 Infection: A 2-Year Update
Jay Lalezari, Kush Dhody, Ula Kowalczyk, Kazem Kazempour, Nader Pourhassan and Paul J. Maddon
ASM 2018 COMBO Poster
https://content.equisolve.net/_f8eaae214fb1b6...b5fc98.pdf


Primary Efficacy Results of PRO 140 SC in a Pivotal Phase 2b/3 Study in Heavily Treatment-Experienced HIV-1 Patients
ASM 2018 COMBO Poster
Kush Dhody, Kazem Kazempour, Nader Pourhassan and Paul J. Maddon
https://content.equisolve.net/_f8eaae214fb1b6...c8e1bd.pdf


PRO 140 (leronlimab) SC: Long-Acting Single-Agent Maintenance Therapy
CROI 2019 MONO Poster
Kush Dhody, Kazem Kazempour, Nader Pourhassan and Paul J. Maddon
http://www.croiconference.org/sites/default/f...y_0486.pdf


Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer metastasis and enhances cell death induced by DNA damaging chemotherapy
Xuanmao Jiao, Min Wang, Zhiping Li, Richard G. Pestell
AACR 2019
https://s3.amazonaws.com/content.stockpr.com/...%20(1).pdf



Final Results of the Pivotal Study of PRO 140 SC in Heavily Treatment-Experienced HIV Patients
Kush Dhody, Kazem Kazempour, Nader Pourhassan, and Paul J. Maddon
ASM 2019 COMBO Poster
https://content.equisolve.net/_f8eaae214fb1b6..._Final.pdf


Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology
Xuanmao Jiao, Omar Nawab, Tejal Patel, Andrew V. Kossenkov, Niels Halama, Dirk Jaeger and Richard G. Pestell
Cancer Research Journal, October 2019 Volume 79, Issue 19
https://cancerres.aacrjournals.org/content/79/19/4801.short



Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme
Miha Koprivnikar Kranjc, Metka Novak, Richard G. Pestell, Prof. Tamara T. Lah
The Journal of Association of Radiology and Oncology, Vol 53, Iss 4
https://www.degruyter.com/view/j/raon.2019.53...9-0057.xml

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 7

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
HTX's Strategic Moves in Pakistan: A Crypto Frontier

Updated Category News Views 5

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Davos Healthcare Aims to Revolutionize Hospital Ratings

Updated Category News Views 3

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Continue Reading
Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 5

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 2

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 3

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading
K-Beauty Takes Front Stage at Target Beauty Studio

Updated Category News Views 4

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading

Top 5 Most Recently Viewed Articles

Shell plc: Recent Share Transactions by Management Team

Updated Category News Views 110

Shell plc made some serious moves back in September 2024 that had traders scratching their heads and looking for the fine print. They let loose a slew of notifications about share transactions by its Persons Discharging Managerial Responsibilities (PDMRs), making waves in the market. This isn’t just corporate fluff; it’s a playbook for transparency and compliance that...

Continue Reading
zSpace Faces Class Action Over IPO Missteps: Key Probe

Updated Category News Views 5

Unpacking the Explosive Allegations Against zSpace You think you're safe diving into augmented reality stocks, and then a bombshell lands. zSpace, Inc. (NASDAQ:ZSPC), a supposed leader in AR and VR educational tech, finds itself in the swirling midst of a class action lawsuit. Investors are rattled, and they're not just buzzing because their portfolios took a hit. There's...

Continue Reading
Transforming Spending: WisdomTree's Innovative Feature Launch

Updated Category News Views 164

WisdomTree Introduces Earn-Until-You-Spend Feature WisdomTree, Inc. (NYSE: WT), a leader in financial innovation, has recently announced a significant enhancement to its user experience with the introduction of a new feature allowing customers to utilize their accrued interest from the WisdomTree Government Money Market Digital Fund (WTGXX) as a funding source for the...

Continue Reading
AVITA Medical Set to Share Third Quarter 2025 Results Soon

Updated Category News Views 163

AVITA Medical to Report Financial Results AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a prominent company in therapeutic acute wound care, has made headlines with its upcoming financial disclosure. The firm is set to unveil its third-quarter financial results for 2025 after the U.S. markets close on the scheduled date. This announcement is anticipated by investors who...

Continue Reading
Hyperscale Data Celebrates Sustainable Growth with Dividends

Updated Category News Views 45

Hyperscale Data's Commendable Dividend Achievement LAS VEGAS — Hyperscale Data, Inc. (NYSE: GPUS) proudly announced it has consistently paid cash dividends for twenty-eight consecutive months on its Series D Preferred Stock. This dividend, amounting to 13.00% annually, equates to approximately $0.2708 for each share, paid monthly. This remarkable track record...

Continue Reading